Ascendis Pharma (NASDAQ):ASND) is without doubt one of the most profitable growth stocks to buy. On Could 7, Ascendis Pharma reported sturdy monetary outcomes for Q1 2026, reaching a complete income of €247 million. This progress was primarily pushed by YORVIPATH, which generated €197 million, alongside €44 million from SKYTROFA. Moreover, the corporate introduced an settlement to promote its Uncommon Pediatric Illness Precedence Assessment Voucher for $187.5 million, additional strengthening its monetary place.
The corporate is experiencing sturdy business momentum, highlighted by over 1,000 new US affected person enrollments for YORVIPATH and greater than 60 enrollments for YUVIWEL following its early April launch. Ascendis can be advancing its medical pipeline, together with optimistic outcomes from the COACH mixture remedy trial, whereas making the strategic choice to discontinue inner oncology improvement to higher align with its long-term focus.
Operational updates for the quarter embody a transition to buying and selling unusual shares on the Nasdaq World Choose Market and the complete redemption of its 2028 convertible notes. With a internet revenue of €629 million and money reserves of €573 million as of March 31, Ascendis Pharma (NASDAQ:ASND) continues to solidify its function as a number one world biopharmaceutical agency.
Ascendis Pharma (NASDAQ:ASND) develops TransCon-based therapies for unmet medical wants.
Whereas we acknowledge the potential of ASND as an funding, we imagine sure AI shares provide higher upside potential and carry much less draw back threat. Should you’re in search of a particularly undervalued AI inventory that additionally stands to profit considerably from Trump-era tariffs and the onshoring pattern, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.
Disclosure: None. Follow Insider Monkey on Google News.
